Abstract LB422: Selective targeting of CDK2 using molecular glue degraders for the treatment of HR-positive/HER2-negative breast cancer

Gkountela, Sofia; Tahaney, William; Vafeiadou, Vasiliki; Bianda, Christelle; Cheeseman, Liam; Singh, Ambika; Diesslin, Anna; Schillo, Martin; Nguyen, Sophia; Moccia, Luca; King, Christopher; Liu, Yimao; Quan, Chao; DeMarco, Bradley; Schwander, Laura; Strande, Vaik; Alers, Jessica; Narayan, Rajiv; Peck, Dave; Pessa, Sarah; Gilberto, Samuel; Castle, John; Janku, Filip; Townson, Sharon; Warmuth, Markus; Walter, Magnus; Ranieri, Beatrice; Tiedt, Ralph; Widlund, Nina Ilic

doi:10.1158/1538-7445.am2025-lb422

Abstract LB422: Selective targeting of CDK2 using molecular glue degraders for the treatment of HR-positive/HER2-negative breast cancer

Cyclin dependent kinases 4 and 6 (CDK4 and CDK6) and cyclin dependent kinase 2 (CDK2) act in a coordinated fashion to phosphorylate and repress RB protein, effectively driving cell proliferation via E2F activation. Currently, CDK4/6 inhibitors in combination with endocrine therapy are considered …